from Leanne Berkahn (President), Steven Lane (Vice President), on behalf of the HSANZ Council and Nada Hamad, HSANZ Member.
The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following AstraZeneca COVID-19 Vaccination. This is a rapidly evolving field and the clinical data are still emerging. HSANZ aims to facilitate dissemination of information as it becomes available.
The HSANZ will not comment on individual cases however, the following resources may be useful in supporting clinicians and patients. The content and recommendations are not specifically endorsed by HSANZ. Our webpage will be updated as more information/resources emerge.
2nd April 2021 TGA Media Release: Specific Clotting Condition reported after COVID-19 Vaccination 2nd April 2021 ATAGI media release: ATAGI statement on COVID-19 vaccination and a reported case of thrombosisCOVID-19 Advisory for Ontario Canada VIPIT Guidance
British Society of Haematology VIPIT Guidance
German Thrombosis and Haemostasis Society VIPIT Guidance
The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) has released a statement on the testing of VIPIT in Australia and New Zealand. For the full statement please go to the HSANZ Members only site.
Statement regarding the potential risk of thrombotic/bleeding events after COVID‐19 vaccination
Date of preparation: 6 April, 2021
The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following COVID-19 Vaccination.
The following resources are available for clinicians and others seeking information on the topic. Note, these resources are linked for general interest and the content and recommendations are not specifically endorsed by HSANZ.
The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) has released a statement on the testing of VIPIT.
For the full statement please go to the HSANZ Members only site
The Kanematsu Research Award is made annually by the Kanematsu Fund in memory of its founder Fusajiro Kanematsu and his wife Sen. The award is made for a single medical research project in the area of haematological disorders.
All information is available on the RCPA website with more information here
Closing date: 30 June 2021
For any questions, contact Eve Propper
The webinar is about Zainab’s Story and the international effort to find rare blood to save this young girl’s life.
The webinar will be presented by a host of presenters from the USA beginning with Dr Richard Gammon and includes Nancy Benitez (OneBlood USA), Sandra Nance (Rare Donor Program American Red Cross) and Tanya Powley (Australian Red Cross Lifeblood) as they share how they searched the world to find compatible blood for Zainab, a two-year-old girl with a rare blood group.
There will be opportunity for a live Q&A from the audience with all the presenters at the end of the presentation.
When: 8:00am AEDT Tuesday 30 March 2021
To register: Visit ANZSBT website and click on the link
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. The second webinar of 2021 features Assistant Professor Saar Gill from the University of Pennsylvania, whose research laboratory currently focuses on the interface between adoptive cellular therapy and genetic engineering, and he is currently leading several clinical trials of CAR T cells for chronic and acute leukaemia. In this webinar, A/Prof Gill will provide valuable insights into the developments being made in role of CAR T cells for the treatment of myeloid malignancies.
A/Professor Saar Gill – Perelman School of Medicine, University of Pennsylvania
When: Monday 22 March 2021, 8am AEDT
Link to webinar:
Link to CBTCT website for all webinar recordings:
For more formation - link
NHMRC Centre for Blood Transplant and Cell Therapies Webinar 15 March 2021
The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant. In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation. The first webinar of 2021 features presentations of two emerging areas of interest in the allogeneic stem cell transplantation field, with Prof David Gottlieb outlining the potential of adoptive T cell therapies for the treatment of invasive fungal infections following allogeneic stem cell transplantation and Dr Abir Bhattacharyya outlining approaches to managing donor specific antibodies in the context of haploidentical stem cell transplantation.
Professor David Gottlieb – Westmead Hospital and the University of Sydney
Dr Abir Bhattacharyya – Westmead Hospital
When: Monday 15 March 2021, 12pm AEDT
For more information click here
The 2021 Highlights of ASH has officially commenced!
This year’s all-virtual experience will take place between March 1 and April 2 and will feature curated annual meeting content that is relevant to all regions in which ASH has historically presented, including North America, the Mediterranean, Asia-Pacific, and Latin America. Attendees will receive full access to the entire program and content on the virtual platform until April 2, including:
The deadline for letters of intent for the LLS/Snowdome Foundation/Leukaemia Foundation co-funded Translational Research Program grants has been extended to the 8th of March.
The Leukemia & Lymphoma Society-Snowdome Foundation-Leukemia Foundation are jointly funding up to two Translational Research Program (TRP) grants at $600,000 (USD) each.
These co-funded blood cancer TRPs are available to researchers working in Australia, Australian investigators working in other countries or to Australian and non-Australian researchers jointly applying as co-PIs.
Letter of intent to be received by March 8th, 2021
Full applications to be received by April 19th, 2021
If you are interested, kindly view this document and respond accordingly
The HSANZ Nurses Group Myeloma Specialist Practice Network is a very active group, with Tracy King at the helm. She not only applied for and received funding from a pharma company, however, also received an Innovation Award for developing MyeTxScheduler, a tool for clinicians to create treatment schedules to help patients to adhere to treatment protocols. The tool is pre-populated with standard myeloma treatment scheduled based on eviQ protocols, with flexibility to adapt to individual patient needs.
It is being rolled out in stages across Australia and New Zealand.
More details here
HSANZ New Zealand branch
Park Hyatt Auckland
11-13 April 2021
Registration is open
Click here to register
For a Program with full speaker details, social functions and accommodation booking information, together with abstract submission details,
Download program here
Haematology Society of Australia and New Zealand (HSANZ)
145 Macquarie Street, Sydney NSW 2000
Tel: 02 8097 8114
Copyright © 2020 Haematology Society of Australia & New Zealand (HSANZ). All Rights Reserved.